3.4.23.5 (3S,4S)-4-(2-[4-[4-amino-3-(4-chlorophenyl)butanoyl]-1-[([1,1'-biphenyl]-4-yl)methyl]piperazin-2-yl]acetamido)-N-butyl-3-hydroxy-5-phenylpentanamide - 235597 3.4.23.5 (3S,4S)-5-(4-bromobenzyloxy)-3-hydroxy-4-(2-thiophen-2-ylacetylamino)pentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide - 13961 3.4.23.5 (3S,4S)-5-(4-bromobenzyloxy)-4-(3,3-diphenylpropionylamino)-3-hydroxypentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide - 13960 3.4.23.5 (3S,4S)-5-(4-bromobenzyloxy)-4-diphenylacetylamino-3-hydroxypentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide - 13959 3.4.23.5 (3S,4S)-N-butyl-3-hydroxy-5-phenyl-4-[2-(4-[4-[(propan-2-yl)oxy]benzoyl]-1-[(3,4,5-trimethoxyphenyl)methyl]piperazin-2-yl)acetamido]pentanamide - 235598 3.4.23.5 (4'S)-3-(2-fluoropyridin-4-yl)-7-[5-(prop-1-yn-1-yl)pyridin-3-yl]-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-2'-amine - 235602 3.4.23.5 (4'S)-3-(3,6-dihydro-2H-pyran-4-yl)-7-[5-(prop-1-yn-1-yl)pyridin-3-yl]-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-2'-amine - 235603 3.4.23.5 (4'S)-3-(3,6-dihydro-2H-pyran-4-yl)-7-[5-[(3-methyloxetan-3-yl)ethynyl]pyridin-3-yl]-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-2'-amine - 235604 3.4.23.5 (4'S)-3-(5,6-dihydro-2H-pyran-3-yl)-1-fluoro-7-(2-fluoropyridin-3-yl)-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-2'-amine - 235605 3.4.23.5 (4'S)-3-(5,6-dihydro-2H-pyran-3-yl)-7-[5-(prop-1-yn-1-yl)pyridin-3-yl]-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-2'-amine - 235606 3.4.23.5 (4'S)-3-chloro-7-(5-fluoropyridin-3-yl)-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-2'-amine - 235607 3.4.23.5 (4'S)-3-chloro-7-[5-(prop-1-yn-1-yl)pyridin-3-yl]-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-2'-amine - 235608 3.4.23.5 (4'S)-3-methoxy-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazole]-2',7-diamine - 235609 3.4.23.5 (4'S)-7-(2-fluoropyridin-3-yl)-3-(2-fluoropyridin-4-yl)-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-2'-amine - 235610 3.4.23.5 (4'S)-7-[5-(cyclopropylethynyl)pyridin-3-yl]-3-(3,6-dihydro-2H-pyran-4-yl)-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-2'-amine - 235611 3.4.23.5 (5S,8S,11S,12S,16S)-8-(3-amino-3-oxopropyl)-11-benzyl-12-hydroxy-7-methyl-16-(2-methylpropyl)-3,6,9,14-tetraoxo-1-phenyl-5-(propan-2-yl)-2-oxa-4,7,10,15-tetraazaheptadecan-17-oic acid - 235643 3.4.23.5 (5S,8S,11S,12S,16S,19S)-8-(3-amino-3-oxopropyl)-11-benzyl-12-hydroxy-7,19-dimethyl-16-(2-methylpropyl)-3,6,9,14,17-pentaoxo-1-phenyl-5-(propan-2-yl)-2-oxa-4,7,10,15,18-pentaazaicosan-20-oic acid - 235644 3.4.23.5 (5S,8S,11S,12S,16S,19S,22R)-8-(3-amino-3-oxopropyl)-11,22-dibenzyl-12-hydroxy-7,19,21-trimethyl-16-(2-methylpropyl)-3,6,9,14,17,20-hexaoxo-1-phenyl-5-(propan-2-yl)-2-oxa-4,7,10,15,18,21-hexaazatricosan-23-oic acid - 235645 3.4.23.5 (5Z)-5-[4-[(4-benzoyl-3-hydroxy-2-propylphenoxy)methyl]benzylidene]-2-thioxo-1,3-thiazolidin-4-one - 202112 3.4.23.5 (6S,9S,12S,13S,17S)-9-(3-amino-3-oxopropyl)-12-benzyl-13-hydroxy-2,2,8-trimethyl-17-(2-methylpropyl)-4,7,10,15-tetraoxo-6-(propan-2-yl)-3-oxa-5,8,11,16-tetraazaoctadecan-18-oic acid - 235657 3.4.23.5 (6S,9S,12S,13S,17S,20S)-9-(3-amino-3-oxopropyl)-12-benzyl-13-hydroxy-2,2,8,20-tetramethyl-17-(2-methylpropyl)-4,7,10,15,18-pentaoxo-6-(propan-2-yl)-3-oxa-5,8,11,16,19-pentaazahenicosan-21-oic acid - 235658 3.4.23.5 (6S,9S,12S,13S,17S,20S,23R)-9-(3-amino-3-oxopropyl)-12,23-dibenzyl-13-hydroxy-2,2,8,20,22-pentamethyl-17-(2-methylpropyl)-4,7,10,15,18,21-hexaoxo-6-(propan-2-yl)-3-oxa-5,8,11,16,19,22-hexaazatetracosan-24-oic acid - 235659 3.4.23.5 (NH4)2SO4 - 399 3.4.23.5 (S)-2,3-dihydro-1H-indole-2-carboxylic acid ((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)amide - 24099 3.4.23.5 1,2-epoxy-3-(4-nitrophenoxy)propane - 1315 3.4.23.5 1,2-epoxy-3-(p-nitrophenoxy)-propane 4.5 mM, 68% residual activity 33803 3.4.23.5 2-(3,4-dimethoxyphenyl)-N-[N-(4-methylbenzyl)carbamimidoyl]acetamide - 202116 3.4.23.5 2-aminobenzoyl-AFKFFSRQ-N-(2,4-dinitrophenyl)ethylenediamine - 54373 3.4.23.5 2-aminobenzoyl-AIHFFSRQ-N-(2,4-dinitrophenyl)ethylenediamine - 54372 3.4.23.5 2-aminobenzoyl-AIKFFHRQ-N-(2,4-dinitrophenyl)ethylenediamine - 54374 3.4.23.5 2-aminobenzoyl-AIKFFPRQ-N-(2,4-dinitrophenyl)ethylenediamine - 54375 3.4.23.5 2-aminobenzoyl-AIKFFSFQ-N-(2,4-dinitrophenyl)ethylenediamine - 54376 3.4.23.5 2-aminobenzoyl-AIKIISRQ-N-(2,4-dinitrophenyl)ethylenediamine - 54370 3.4.23.5 2-aminobenzoyl-AIKQQSRQ-N-(2,4-dinitrophenyl)ethylenediamine - 54371 3.4.23.5 2-aminobenzoyl-AIKVVSRQ-N-(2,4-dinitrophenyl)ethylenediamine - 54369 3.4.23.5 2-bromo-N-[(2S,3S)-4-[[2-(2,4-dichlorophenyl)ethyl][3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanoyl]amino]-3-hydroxy-1-(3-phenoxyphenyl)butan-2-yl]-4,5-dimethoxybenzamide - 202111 3.4.23.5 2-mercaptoethanol - 63 3.4.23.5 3,5-dichloro-2-[[(3,5-dichloro-2-hydroxyphenyl)sulfonyl]amino]-N-[4-[(6-ethoxy-1,3-benzothiazol-2-yl)sulfanyl]phenyl]benzamide - 202113 3.4.23.5 3-cyclohexyl-N-(3,4-difluorobenzyl)-N2-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-D-alaninamide - 202131 3.4.23.5 3-cyclohexyl-N-(3,4-dimethoxybenzyl)-N2-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-D-alaninamide - 202127 3.4.23.5 3-cyclohexyl-N2-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-N-(3-fluoro-4-methoxybenzyl)-D-alaninamide - 202130 3.4.23.5 3-cyclohexyl-N2-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-N-(4-fluoro-3-methoxybenzyl)-D-alaninamide - 202129 3.4.23.5 3-cyclohexyl-N2-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-N-[3-(1H-tetrazol-5-yl)benzyl]-D-alaninamide - 202133 3.4.23.5 3-cyclohexyl-N2-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-N-[3-fluoro-4-(1H-tetrazol-5-yl)benzyl]-D-alaninamide - 202135 3.4.23.5 3-cyclohexyl-N2-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-N-[4-(1H-tetrazol-5-yl)benzyl]-D-alaninamide - 202134 3.4.23.5 3-indolepyruvate - 8006 3.4.23.5 3-p-hydroxyphenylpyruvate - 97341 3.4.23.5 3-phenylpyruvate - 4914 3.4.23.5 3-[5-[(4'S)-2'-amino-3-(3,6-dihydro-2H-pyran-4-yl)-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-7-yl]pyridin-3-yl]prop-2-yn-1-ol - 236187 3.4.23.5 4-([N-[(benzyloxy)carbonyl]-L-valyl-N2-methyl-L-glutaminyl]amino)-2,4,5-trideoxy-5-phenyl-L-threo-pentonic acid - 236224 3.4.23.5 4-bromophenacyl bromide - 5353 3.4.23.5 4-bromophenylacylbromide - 99867 3.4.23.5 6-aminohexanoate - 2718 3.4.23.5 Ascaris inhibitor - 100137 3.4.23.5 ascorbic acid - 387 3.4.23.5 Ba2+ 54% residual activity at 5 mM 111 3.4.23.5 cathepsin D inhibitor from Streptomyces sp.MBR04 reversible, competitive, slow-tight-binding inhibitor 202110 3.4.23.5 CEL5-A disruption of single- to heavy-chain formation 118081 3.4.23.5 CEL5-G disruption of single- to heavy-chain formation 118082 3.4.23.5 Chloroquine - 1439 3.4.23.5 CN- - 159 3.4.23.5 Diazoacetyl-DL-norleucine methyl ester - 1233 3.4.23.5 Diazoacetyl-DL-norleucine methyl ester 0.05 mM, 66% residual activity 1233 3.4.23.5 Diazoacetylglycine ethyl ester - 44035 3.4.23.5 dithioerythritol - 577 3.4.23.5 dithiothreitol 10 mM, 90% inhibition 45 3.4.23.5 dithiothreitol - 45 3.4.23.5 dithiothreitol strong inhibitor 45 3.4.23.5 DMSO in the presence of 10% (v/v) DMSO a significant decrease in activity to 40% is observed. In 25% (v/v) DMSO the enzyme maintains 20% of the activity. Activity is completely lost when the enzyme is exposed to DMSO at concentration above 35% (v/v) 896 3.4.23.5 DNA18b i.e. 5’-ggctcaggtacccagaga-3’, at 100 nM, 40% inhibition 118079 3.4.23.5 DNA53b i.e. 5’-gctctagatcaatgatgatgatgatgatgctggcgtttccgaggggggcgctt-3’, 80% inhibition at 100 nM, complete inhibition at 0.001 mM 118080 3.4.23.5 E-64 83% residual activity at 1 mM 559 3.4.23.5 EA-1 disruption of single- to heavy-chain formation 118083 3.4.23.5 EDTA 10 mM, slight 21 3.4.23.5 EDTA no significantly influenced 21 3.4.23.5 equistatin - 163351 3.4.23.5 ethanol 5% 69 3.4.23.5 ethanol high-proof alcoholic beverages 69 3.4.23.5 ethanol at 25 and 35% (v/v) ethanol, enzyme activity decreases to 60 and 40%, respectively. In 50% ethanol, the enzyme completely loses its activity 69 3.4.23.5 ethyl 6-(2-[[(2S,3S)-5-(butylamino)-3-hydroxy-5-oxo-1-phenylpentan-2-yl]carbamoyl]-4-[3-(3,4,5-trimethoxyphenyl)propanoyl]piperazin-1-yl)-6-oxohexanoate - 236437 3.4.23.5 Fe2+ - 25 3.4.23.5 Fe2+ 68% residual activity at 5 mM 25 3.4.23.5 Fe3+ FeCl3 70 3.4.23.5 Fe3+ - 70 3.4.23.5 Fe3+ 12.4% residual activity at 5 mM 70 3.4.23.5 H-256 i.e. L-Glu-L-Pro-L-Thr-L-alpha-Glu-L-Phe-PSI[CH2-NH]-L-Phe-L-Arg 44206 3.4.23.5 H-261 i.e. L-His-L-His-L-Pro-L-Phe-L-His-(2S,4S,5S)-5-amino-4-hydroxy-7-methyl-2-(1-methylethyl)octanoyl-L-Ile 20292 3.4.23.5 Hg2+ Hg(CH3COO)2 33 3.4.23.5 Hg2+ - 33 3.4.23.5 Hg2+ 10 mM, 46% inhibition 33 3.4.23.5 Hg2+ Hg(NO3)2 33 3.4.23.5 Hg2+ 20 mM, 50% inhibition 33 3.4.23.5 Hg2+ 26.2% residual activity at 5 mM 33 3.4.23.5 I- - 507 3.4.23.5 inhibitor isolated from potato - 54378 3.4.23.5 inhibitor isolated from potatoes - 47287 3.4.23.5 inhibitor isolated from tomato recombinant protein, GenBank accession no. AJ289776 54377 3.4.23.5 iodoacetic acid 76% residual activity at 1 mM 213 3.4.23.5 Isopropanol at 25% (v/v) isopropanol, the enzyme activity drops to 50%, enzyme activity is completely lost at 35% (v/v) 958 3.4.23.5 isovaleryl-pepstatin - 21160 3.4.23.5 Kallikrein - 12929 3.4.23.5 KCl - 79 3.4.23.5 L-363,564 - 46021 3.4.23.5 L-Cys - 336 3.4.23.5 lactoyl-pepstatin - 16301 3.4.23.5 methanol the enzyme loses activity in the presence of more than 35% (v/v) methanol 83 3.4.23.5 methyl (2S)-1-[(2R,5S,8S,12S,13S)-2,13-dibenzyl-12-hydroxy-15-(3-[(methanesulfonyl)(methyl)amino]-5-[[(1R)-1-phenylethyl]carbamoyl]phenyl)-3,5-dimethyl-8-(2-methylpropyl)-4,7,10,15-tetraoxo-3,6,9,14-tetraazapentadecanan-1-oyl]pyrrolidine-2-carboxylate - 236452 3.4.23.5 methyl (5S,8S,11S,12S,16S)-8-(3-amino-3-oxopropyl)-11-benzyl-12-hydroxy-7-methyl-16-(2-methylpropyl)-3,6,9,14-tetraoxo-1-phenyl-5-(propan-2-yl)-2-oxa-4,7,10,15-tetraazaheptadecan-17-oate - 236454 3.4.23.5 methyl (5S,8S,11S,12S,16S,19S)-8-(3-amino-3-oxopropyl)-11-benzyl-12-hydroxy-7,19-dimethyl-16-(2-methylpropyl)-3,6,9,14,17-pentaoxo-1-phenyl-5-(propan-2-yl)-2-oxa-4,7,10,15,18-pentaazaicosan-20-oate - 236455 3.4.23.5 methyl (5S,8S,11S,12S,16S,19S,22R)-8-(3-amino-3-oxopropyl)-11,22-dibenzyl-12-hydroxy-7,19,21-trimethyl-16-(2-methylpropyl)-3,6,9,14,17,20-hexaoxo-1-phenyl-5-(propan-2-yl)-2-oxa-4,7,10,15,18,21-hexaazatricosan-23-oate - 236456 3.4.23.5 methyl (6S,9S,12S,13S,17S)-9-(3-amino-3-oxopropyl)-12-benzyl-13-hydroxy-2,2,8-trimethyl-17-(2-methylpropyl)-4,7,10,15-tetraoxo-6-(propan-2-yl)-3-oxa-5,8,11,16-tetraazaoctadecan-18-oate - 236457 3.4.23.5 methyl (6S,9S,12S,13S,17S,20S)-9-(3-amino-3-oxopropyl)-12-benzyl-13-hydroxy-2,2,8,20-tetramethyl-17-(2-methylpropyl)-4,7,10,15,18-pentaoxo-6-(propan-2-yl)-3-oxa-5,8,11,16,19-pentaazahenicosan-21-oate - 236458 3.4.23.5 methyl (6S,9S,12S,13S,17S,20S,23R)-9-(3-amino-3-oxopropyl)-12,23-dibenzyl-13-hydroxy-2,2,8,20,22-pentamethyl-17-(2-methylpropyl)-4,7,10,15,18,21-hexaoxo-6-(propan-2-yl)-3-oxa-5,8,11,16,19,22-hexaazatetracosan-24-oate - 236459 3.4.23.5 Mn2+ 0.01 M, slight decrease in activity 11 3.4.23.5 Mn2+ 32.5% residual activity at 5 mM 11 3.4.23.5 molybdate 2.3% residual activity at 1 mM 509 3.4.23.5 Monoiodoacetic acid - 2275 3.4.23.5 additional information - 2 3.4.23.5 additional information not inhibitory: antipain, chymostatin, o-phenanthroline, phenylmethylsulfonylfluoride, iodoacetamide 2 3.4.23.5 additional information inhibitory activity of DNA is significantly dependent on Tm values of each nucleotide 2 3.4.23.5 additional information no inhibition by Ascaris pepsin inhibitor 2 3.4.23.5 additional information no inhibition by iodoacetamide and E64 (inhibitors for cysteine proteases), leupeptin, and phenylmethanesulfonyl fluoride (inhibitors for serine proteases) or EDTA and 1,10-phenanthroline (inhibitors for metalloproteases) 2 3.4.23.5 additional information when released into the plasma, cath-D is inactivated by its interaction with alpha2-macroglobulin at a neutral pH, but not at an acidic pH. DNA fragments can inhibit cath-D proteolytic activity 2 3.4.23.5 additional information cathepsin D has neither endogenous lysosomal nor cytosolic inhibitors 2 3.4.23.5 additional information not affected by 0.02 mM soybean trypsin inhibitor, 0.02 mM leupeptin, and 0.02 mM E-64 2 3.4.23.5 additional information not inhibited by E-64, leupeptin, and phenylmethylsulfonyl fluoride 2 3.4.23.5 additional information no inhibition with phenylmethylsulfonyl fluoride, benzamidine, soybean trypsin inhibitor, TPCK, and EDTA 2 3.4.23.5 additional information not inhibited by diazoacetyl-DL-norleucine methyl ester 2 3.4.23.5 additional information not inhibited by paclitaxel 2 3.4.23.5 N-((1S,2S)-1-(4-benzo[1,3]dioxol-5-yl-benzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propyl)-2,4,6-trifluorobenzamide - 13969 3.4.23.5 N-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-3,4-dichlorobenzamide - 13958 3.4.23.5 N-((1S,2S)-1-(biphenyl-4-ylmethoxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propyl)-2,4,6-trifluorobenzamide - 13967 3.4.23.5 N-(3,4-dimethoxybenzyl)-N2-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-D-leucinamide - 202128 3.4.23.5 N-(3,4-dimethoxybenzyl)-Na-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-D-phenylalaninamide - 202126 3.4.23.5 N-(N-benzylcarbamimidoyl)-2-(2-chloro-5-methoxyphenyl)acetamide - 202119 3.4.23.5 N-(N-benzylcarbamimidoyl)-2-(4,5-dimethoxy-2-nitrophenyl)acetamide - 202120 3.4.23.5 N-(N-benzylcarbamimidoyl)-3-(3,4-dimethoxyphenyl)propanamide - 202122 3.4.23.5 N-(N-benzylcarbamimidoyl)-4-(4,5-dimethoxy-2-nitrophenyl)butanamide - 202121 3.4.23.5 N-bromosuccinimide 0.05 mM, 50% inhibition 208 3.4.23.5 N-[(1S,2S)-1-(biphenyl-4-ylmethoxymethyl)-3-cyclo-hexylcarbamoyl-2-hydroxypropyl]-2,4,6-trifluorobenzamide - 13970 3.4.23.5 N-[(1S,2S)-3-cyclohexylcarbamoyl-2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)-propyl]-2,4,6-trifluorobenzamide - 13971 3.4.23.5 N-[(1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butyl-carbamoyl)-ethylcarbamoyl]-2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)-propyl]-2,4,6-trifluorobenzamide - 13968 3.4.23.5 N-[(2S,3S)-5-(butylamino)-3-hydroxy-5-oxo-1-phenylpentan-2-yl]-1-[2-(2-phenylethoxy)ethyl]-4-[3-(3,4,5-trimethoxyphenyl)propanoyl]piperazine-2-carboxamide - 236838 3.4.23.5 N-[(4'S)-2'-amino-3-(3,6-dihydro-2H-pyran-4-yl)-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-7-yl]-5-chloropyridine-2-carboxamide - 236860 3.4.23.5 N-[(4'S)-2'-amino-3-(5,6-dihydro-2H-pyran-3-yl)-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-7-yl]-5-chloropyridine-2-carboxamide - 236861 3.4.23.5 N-[(4'S)-2'-amino-3-chloro-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-7-yl]-5-chloropyridine-2-carboxamide - 236862 3.4.23.5 N-[(4'S)-2'-amino-3-cyclopropyl-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-7-yl]-5-chloropyridine-2-carboxamide - 236863 3.4.23.5 N-[(4'S)-2'-amino-3-methoxy-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-7-yl]-5-chloropyridine-2-carboxamide - 236864 3.4.23.5 N-[(4'S)-2'-amino-3-methyl-5'H-spiro[[1]benzopyrano[2,3-c]pyridine-5,4'-[1,3]oxazol]-7-yl]-5-chloropyridine-2-carboxamide - 236865 3.4.23.5 N-[N-(2-chlorobenzyl)carbamimidoyl]-2-(4,5-dimethoxy-2-nitrophenyl)acetamide - 202118 3.4.23.5 N-[N-(3,4-dichlorobenzyl)carbamimidoyl]-2-(4,5-dimethoxy-2-nitrophenyl)acetamide - 202114 3.4.23.5 N-[N-(3,4-dimethoxybenzyl)carbamimidoyl]-2-(4,5-dimethoxy-2-nitrophenyl)acetamide - 202117 3.4.23.5 N-[N-(4-aminobenzyl)carbamimidoyl]-2-(3,4-dimethoxyphenyl)acetamide - 202123 3.4.23.5 N-[N-(4-chlorobenzyl)carbamimidoyl]-2-(4,5-dimethoxy-2-nitrophenyl)acetamide - 202115 3.4.23.5 N1-[(2S,3S)-3-hydroxy-5-([(2S)-4-methyl-1-[(2-methylpropyl)amino]-1-oxopentan-2-yl]amino)-5-oxo-1-phenylpentan-2-yl]-5-[(methanesulfonyl)(methyl)amino]-N3-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide - 236942 3.4.23.5 N1-[(2S,3S)-3-hydroxy-5-[[(2S)-1-[[(3-methoxyphenyl)methyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxo-1-phenylpentan-2-yl]-5-[(methanesulfonyl)(methyl)amino]-N3-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide - 236943 3.4.23.5 N1-[(2S,3S)-5-[[(2S)-1-(cyclopropylamino)-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-5-oxo-1-phenylpentan-2-yl]-5-[(methanesulfonyl)(methyl)amino]-N3-[(1R)-1-phenylethyl]benzene-1,3-dicarboxamide - 236944 3.4.23.5 N2-[N-[(2-bromo-4,5-dimethoxyphenyl)acetyl]carbamimidoyl]-3-cyclohexyl-N-(4-fluoro-3-methoxybenzyl)-D-alaninamide - 202140 3.4.23.5 N2-[N-[(2-bromo-4,5-dimethoxyphenyl)acetyl]carbamimidoyl]-3-cyclohexyl-N-[3-(1H-tetrazol-5-yl)benzyl]-D-alaninamide - 202141 3.4.23.5 N2-[N-[(2-bromo-4,5-dimethoxyphenyl)acetyl]carbamimidoyl]-N-[3-(1H-tetrazol-5-yl)benzyl]-D-leucinamide - 202142 3.4.23.5 N2-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-N-(4-fluoro-3-methoxybenzyl)-D-leucinamide - 202132 3.4.23.5 N2-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-N-[2-fluoro-3-(1H-tetrazol-5-yl)benzyl]-D-leucinamide - 202137 3.4.23.5 N2-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-N-[3-(1H-tetrazol-5-yl)benzyl]-D-leucinamide - 202136 3.4.23.5 N2-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-N-[3-fluoro-4-(1H-tetrazol-5-yl)benzyl]-D-leucinamide - 202139 3.4.23.5 N2-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-N-[4-(1H-tetrazol-5-yl)benzyl]-D-leucinamide - 202138 3.4.23.5 Na-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-N-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-D-phenylalaninamide - 202124 3.4.23.5 Na-[N-[(3,4-dimethoxyphenyl)acetyl]carbamimidoyl]-N-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]-L-phenylalaninamide - 202125 3.4.23.5 NaCl 10%, almost complete inactivation 42 3.4.23.5 NaCl purified enzyme retains more than 50% of proteolytic activity in final concentration of 1 M NaCl and 20% in 1.5 M NaCl 42 3.4.23.5 Pb2+ Pb(NO3)2 139 3.4.23.5 Pb2+ cathepsin D-II inhibited, cathepsin D-I hardly affected 139 3.4.23.5 PCMB - 78 3.4.23.5 pepstatin 0.001 mM, complete inhibition 396 3.4.23.5 pepstatin strong 396 3.4.23.5 pepstatin - 396 3.4.23.5 pepstatin pepstatin A 396 3.4.23.5 pepstatin complete inhibition at 0.02 mM 396 3.4.23.5 pepstatin A Ki-values for pepstatin A, modified at Pµ3, Pµ2, P1, or P2 position, entropy plays a major stabilizing role in inhibitor binding to cathepsin D 309 3.4.23.5 pepstatin A pretreatment inhibits apoptosis in cells exposed to naphthazarin (5,8-dihydroxy-1,4-naphthoquinone) 309 3.4.23.5 pepstatin A prevents release of enzyme and cytochrome c to cytosol upon treatment with staurosporine 309 3.4.23.5 pepstatin A 0.01 mM, no residual activity 309 3.4.23.5 pepstatin A - 309 3.4.23.5 pepstatin A strongly inhibits the cleavage of wild-tpye and mutated Swedish family peptide substrate bearing two mutated residues in the beta-site of the amyloid precursor protein 309 3.4.23.5 pepstatin A it is shown that Pepstatin A prevents polyphenol resveratrol (RV)-mediated cytotoxicity in human colorectal cancer cells 309 3.4.23.5 pepstatin A blocking the activity of CTSD reduces ABCA1 expression and protein abundance in both macrophages and CHO cells and apolipoprotein A-I-mediated lipid efflux by more than 70%. Consistent with its role in the proteolytic processing of prosaposin, inactivation of CTSD function results in the accumulation of glycosphingolipid and free cholesterol in late endosomes/lysosomes. Inhibition of CTSD also causes retention of ABCA1 in lysosomal compartments, reducing its trafficking to the plasma membrane 309 3.4.23.5 pepstatin A inhibition of cathepsin D results in delayed caspase activation and reduced neutrophil apoptosis 309 3.4.23.5 pepstatin A most potent polypeptide inhibitor of cath-D 309 3.4.23.5 pepstatin A specific inhibitor 309 3.4.23.5 pepstatin A cathepsin D inhibitor 309 3.4.23.5 pepstatin A specific cathepsin D inhibitor 309 3.4.23.5 pepstatin A completely inhibited by 0.0015 mM pepstatin A 309 3.4.23.5 pepstatin A strong inhibitor 309 3.4.23.5 phenylmethanesulfonyl fluoride slight 827 3.4.23.5 phenylpyruvate - 198 3.4.23.5 plasmid DNA length 50 kbp, double strand, 50% inhibition at 60 pM 31902 3.4.23.5 potassium permanganate 0.01 mM, 50% inhibition 16400 3.4.23.5 pyridine-2-carboxylic acid ((R)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide - 13957 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(3-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)-ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methyl-propyl)-amide - 13972 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-benzo-[1,3]dioxol-5-yl-benzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)-amide - 13963 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(2-(3-methoxyphenyl)ethylcarbamoyl)propylcarbamoyl)-2-methylpropyl)amide - 13953 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide - 13950 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(biphenyl-3-ylmethoxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propylcar-bamoyl)-2-methyl-propyl)-amide - 13973 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(biphenyl-4-ylmethoxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propylcarbamoyl)-2-methyl-propyl)-amide - 13962 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-benzyloxymethyl-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide - 13949 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-((1S,2S)-3-((S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl)-2-hydroxy-1-phenethylpropylcarbamoyl)-2-methylpropyl)amide - 35838 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-benzo-[1,3]dioxol-5-yl-benzyloxymethyl)-3-butylcarbamoyl-2-hydroxy-propylcarbamoyl]-2-methyl-propyl)-amide - 13966 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(2-phenylaminoethyl-carbamoyl)propylcarbamoyl]-2-methylpropyl)amide - 13954 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(3-phenylpropylcarbamoyl)propylcarbamoyl]-2-methylpropyl)amide - 13951 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-(4-cyanobenzylcarbamoyl)-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide - 14001 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-(cyclohexylmethylcarbamoyl)-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide - 13952 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-butylcarbamoyl-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide - 13956 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-cyclohexylcarbamoyl-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide - 13955 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(biphenyl-4-ylmethoxymethyl)-3-butylcarbamoyl-2-hydroxy-propylcarbamoyl]-2-methylpropyl)-amide - 13964 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-3-butylcarbamoyl-2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)-propylcarbamoyl]-2-methyl-propyl)-amide - 13965 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)-propyl-carbamoyl]-2-methyl-propyl)-amide - 14002 3.4.23.5 pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-1-(3-thiophen-3-yl-benzyloxymethyl)-propylcarbamoyl]-2-methylpropyl)-amide - 132577 3.4.23.5 pyridine-2-carboxylic acid((S)-1-[(1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)-propyl-carbamoyl]-2-methyl-propyl)-amide - 35840 3.4.23.5 SDS - 124 3.4.23.5 SDS 28% residual activity at 0.2% (w/v) 124 3.4.23.5 sodium lauryl sulfate 0.7 mM, 50% inhibition 3231 3.4.23.5 Soybean trypsin inhibitor - 544 3.4.23.5 tasiamide B - 239977 3.4.23.5 TB-11 - 235174 3.4.23.5 TB-13 - 239978 3.4.23.5 Tb-9 - 235171 3.4.23.5 tosylphenylalanylchloromethane - 20852 3.4.23.5 Triton X-100 60% residual activity at 0.001-0.01% (v/v) Triton X-100, below 20% residual activity at 0.0005% or 0.05-0.1% (v/v) Triton X-100 61 3.4.23.5 Urea - 116 3.4.23.5 Val-D-Leu-Pro-Phe-Phe-Val-D-Leu - 10807 3.4.23.5 Vitamin A - 7302 3.4.23.5 Zn2+ 0.01 M, slight decrease in activity 14